Citizens Cuts AtriCure Price Target, Cites Valuation Reset Despite Operational Momentum
Citizens reduced its price target for AtriCure Inc. to $52 from $60 while keeping a Market Outperform rating. The adjustment reflects a lower EV/revenue multiple consistent with peer valuations and is tied to a revised 2027 sales assumption of $675 million. AtriCure reported stronger-than-expected fourth-quarter 2025 results, with positive adjusted…